Moreover, Wortamannin treatment also resulted in a reduction of HK2 expression in NPC cells and this inhibitory effect was more salient in CNE-LMP1 and HNE2-LMP1 cells (Figure 7e), leading to a much higher dose-dependent inhibition of the glycolytic flux compared with their respective parental cells (Figure 7f). The gene discussed is HK2; the disease is nasopharyngeal carcinoma.